


Recombinant Mouse CTLA-4 Fc Chimera

Catalog Number: 434-CT/CF

DESCRIPTION				
Source	Mouse myeloma cell line, NS0-derived mouse CTLA-4 protein			
	Mouse CTLA-4 Ala37-Phe162 Accession #Q6GTR6	IEGRMD	Human IgG ₁ (Pro100-Lys330)	6-His tag
	N-terminus			C-terminus
N-terminal Sequence Analysis	Ala37			
Structure / Form	Disulfide-linked homodimer			
Predicted Molecular Mass	41 kDa (monomer)			

SPECIFICATIONS		
SDS-PAGE	55 kDa, reducing conditions	
Activity	Measured by its ability to inhibit IL-2 secretion by stimulated Jurkat human acute T cell leukemia cells. Linsley, P.S. <i>et al.</i> (1991) J. Exp. Med. 174 :561. The ED ₅₀ for this effect is 0.1-0.4 μg/mL when stimulated with 1 μg/mL Recombinant Human B7-1/CD80 Fc Chimera (Catalog # 140-B1) in the presence of PHA.	
Endotoxin Level	<0.10 EU per 1 μ g of the protein by the LAL method.	
Purity	>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.	
Formulation	Lyophilized from a 0.2 μm filtered solution in PBS. See Certificate of Analysis for details.	

PREPARATION AND STORAGE			
Reconstitution	Reconstitute at 200 µg/mL in sterile PBS.		
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.		
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.		
	 12 months from date of receipt, -20 to -70 °C as supplied. 		
	1 month, 2 to 8 °C under sterile conditions after reconstitution.		
	 3 months20 to -70 °C under sterile conditions after reconstitution. 		



Recombinant Mouse CTLA-4 Fc Chimera (Catalog # 434-CT) inhibits IL-2 secretion by stimulated Jurkat human acute T cell leukemia cells. The ED₅₀ for this effect is 0.03-0.15 μ g/mL when stimulated with 1 μ g/mL Recombinant Human B7-1/CD80 Fc Chimera (Catalog # 140-B1).

Rev. 11/1/2018 Page 1 of 2



Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956 USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373 Europe | Middle East | Africa TEL +44 (0)1235 529449



Recombinant Mouse CTLA-4 Fc Chimera

Catalog Number: 434-CT/CF

BACKGROUND

CTLA-4 (cytotoxic T-lymphocyte-4, designated CD152), is a type I transmembrane T cell inhibitory molecule that is a member of the Ig superfamily (1, 2). Human or mouse CTLA-4 cDNA encodes 223 amino acids (aa) including a 35 aa signal sequence, a 126 aa extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane (TM) sequence, and a 41 aa cytoplasmic sequence. It is found as a covalent homodimer of 41 - 43 kDa (2) Within the ECD, mouse CTLA-4 shares 94% and 68 - 71% aa sequence identity with rat and human/porcine/bovine/rabbit/feline/canine CTLA-4, respectively. A 174 aa form that lacks TM and cytoplasmic sequences (sCTLA-4) is possibly secreted (3 - 5). Isoforms of 56 - 79 aa that mainly contain parts of the cytoplasmic domain are reported. In mouse, an isoform lacking the Ig-like domain has ligand-independent inhibitory activity and is termed liCTLA-4 (6). CD28, which is structurally related to CTLA-4, is constitutively expressed on naïve T cells and promotes T cell activation when engaged by B7-2 on antigen-presenting cells (APC) within the immunological synapse (IS) (1, 7, 8). In contrast, CTLA-4 is recruited from intracellular vesicles to the IS beginning 1-2 days after T cell activation (2, 7, 8). It forms a linear lattice with B7-1 on APC, inducing B7-1 and B7-2 binding and has been used to antagonize T cell activation in autoimmune conditions and to enhance transplant survival (10). Mice deleted for CTLA-4 show no abnormalities until after birth, but then develop lethal autoimmune reactions due to continued T cell activation and poor control by regulatory T cells, which constitutively express CTLA-4 in wild-type mice and humans (11 - 13).

References:

- 1. Harper, K. et al. (1991) J. Immunol. 147:1037.
- 2. Teft, W.A. et al. (2006) Annu. Rev. Immunol. 24:65.
- 3. Magistrelli, G. et al. (1999) Eur. J. Immunol. 29:3596.
- 4. Tector, M. et al. (2009) BMC Immunol. 10:51.
- 5. Oaks, M.K. and K.M. Hallett (2000) J. Immunol. 164:5015.
- 6. Vijayakrishnan, L. et al. (2004) Immunity 20:563.
- 7. Pentcheva-Hoang, T. et al. (2004) Immunity 21:401.
- 8. Jansson, A. et al. (2005) J. Immunol 175:1575.
- 9. Darlington, P.J. et al. (2005) J. Immunol. 175:996.
- 10. Platt, A.M. et al. (2010) J. Immunol. 185:1558.
- 11. Wing, K. et al. (2008) Science 322:271.
- 12. Friedline, R.H. et al. (2009) J. Exp. Med. 206:421.
- 13. Jain, N. et al. (2010) Proc. Natl. Acad. Sci. USA 107:1524.

Rev. 11/1/2018 Page 2 of 2



Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956 USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373 Europe | Middle East | Africa TEL +44 (0)1235 529449